Format

Send to

Choose Destination
J Neurooncol. 2016 Sep;129(2):195-9. doi: 10.1007/s11060-016-2192-z. Epub 2016 Jul 11.

Clinical ramifications of "genomic staging" of low-grade gliomas.

Author information

1
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
2
Department of Radiation Oncology, Miami Cancer Institute, 1575 San Ignacio Ave, Suite 100, Coral Gables, FL, 33146, USA. mineshpmehta@gmail.com.

Abstract

"Low-grade gliomas" (LGGs), classification of which is derived from histopathological observations, exhibit significant heterogeneity in clinical behavior. Recently, increasing attention has been paid to genomic analyses of these tumors, to aid in treatment and prognostic decision-making. We discuss herein the recent genomic analysis of gliomas from two major recent publications, and also the results of seminal LGG trials in the context of molecular and genomic stratification, with respect to both prognosis and response to therapy. We also analyze implications of these "molecular classifications". We propose separating out the worst prognostic subsets, whose outcomes resemble those of glioblastoma patients. Lastly, a brief discussion is provided regarding translating this collective knowledge into the clinic and in treatment decisions; also addressed are some of the many questions that still need to be examined in light of these strong and emerging data.

KEYWORDS:

Astrocytoma; Genomics; Low-grade glioma; Oligodendroglioma

PMID:
27401152
DOI:
10.1007/s11060-016-2192-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center